Cargando…

Coexpression of EGFR and CXCR4 Predicts Poor Prognosis in Resected Pancreatic Ductal Adenocarcinoma

BACKGROUND: Epidermal growth factor receptor (EGFR) is highly expressed in pancreatic ductal adenocarcinoma (PDAC) and is involved in tumorigenesis and development. However, EGFR expression alone has limited clinical and prognostic significance. Recently, the cross-talk between EGFR and G-protein-co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Huanwen, Zhu, Liang, Zhang, Hui, Shi, Xiaohua, Zhang, Li, Wang, Wenze, Xue, Huadan, Liang, Zhiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332630/ https://www.ncbi.nlm.nih.gov/pubmed/25679210 http://dx.doi.org/10.1371/journal.pone.0116803

Ejemplares similares

Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma
por: Wang, Lili, et al.
Publicado: (2017)

Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma
por: Wang, Li, et al.
Publicado: (2016)

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
por: Li, Ruiyu, et al.
Publicado: (2021)

EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival
por: Fagman, Johan Bourghardt, et al.
Publicado: (2019)

High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Song, Yang, et al.
Publicado: (2020)

Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition
por: Zhang, Zhiwen, et al.
Publicado: (2019)

Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2018)

Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2015)

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
por: Lohneis, Philipp, et al.
Publicado: (2018)

Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma
por: Yang, Jian-Yu, et al.
Publicado: (2015)

Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma
por: Liu, Wen-Jing, et al.
Publicado: (2018)

Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma
por: Zhang, Luan-Jing, et al.
Publicado: (2014)

Corrigendum: Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma
por: Yang, Jian-Yu, et al.
Publicado: (2015)

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
por: Maréchal, R, et al.
Publicado: (2009)

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
por: Maréchal, R, et al.
Publicado: (2010)

Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma
por: Chen, Tao, et al.
Publicado: (2015)

Low Expression of TBX4 Predicts Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma
por: Zong, Meijuan, et al.
Publicado: (2011)

Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma
por: Xu, Xinsen, et al.
Publicado: (2023)

Multi‐omics analysis of intra‐tumoural and inter‐tumoural heterogeneity in pancreatic ductal adenocarcinoma
por: Liu, Xiaoqian, et al.
Publicado: (2022)

PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma
por: Ge, Ouyang, et al.
Publicado: (2021)

High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma
por: Zhou, Cong‐ya, et al.
Publicado: (2018)

CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery
por: Zhu, Liang, et al.
Publicado: (2016)

PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay
por: Liang, Xiaolong, et al.
Publicado: (2018)

Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2021)

DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Yang, Jianyu, et al.
Publicado: (2019)

High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma
por: Huo, Yanmiao, et al.
Publicado: (2015)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

High expression of RACK1 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma
por: Han, Hailin, et al.
Publicado: (2018)

A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis
por: Mohamed Abd-El-Halim, Yousra, et al.
Publicado: (2021)

Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma
por: Huang, Xinyang, et al.
Publicado: (2022)

SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis
por: Ma, Qiang, et al.
Publicado: (2017)

Optical magnetic multimodality imaging of plectin-1-targeted imaging agent for the precise detection of orthotopic pancreatic ductal adenocarcinoma in mice
por: Zhang, Wenjia, et al.
Publicado: (2022)

Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
por: Park, Sejun, et al.
Publicado: (2023)

CXCR4 Expression Predicts Early Liver Recurrence and Poor Survival After Resection of Pancreatic Adenocarcinoma
por: Liao, Wei-Chih, et al.
Publicado: (2012)

High expression of muscarinic acetylcholine receptor 3 predicts poor prognosis in patients with pancreatic ductal adenocarcinoma
por: Zhang, Lingfu, et al.
Publicado: (2016)

Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
por: MacCurtain, Benjamin M., et al.
Publicado: (2021)

High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma
por: Wu, Dong-jin, et al.
Publicado: (2018)

High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma
por: Huang, Jianfei, et al.
Publicado: (2015)

High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma
por: Curia, Maria Cristina, et al.
Publicado: (2019)

High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma
por: Li, He, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3f0j54ek33porrm26tf1fru77